Dr. Andrew Leuchter, director of the Neuromodulation Division, was invited to speak about Transcranial Magnetic Stimulation for treatment-resistant depression at Semel Grand Rounds on September 29th, 2020. You can view his talk above.
|
Efficacy and safety of Transcranial Magnetic Stimulation in the acute treatment of Major Depression: a multisite randomized controlled trial, JP O’Reardon et al, Biological Psychiatry, 2007
This was one of the first major studies demonstrating that TMS is safe and effective for the treatment of depression, and in part led to the FDA approval of TMS in 2008. |
|
A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: Durability of benefit over a 1-year follow-up period. D.L. Dunner et al, Journal of Clinical Psychiatry, 2014.
This important study demonstrated that for many patients, the benefits of TMS can last up to a year or longer after treatment. |
|
A randomized trial of the anti‐depressant effects of low‐ and high‐frequency transcranial magnetic stimulation in treatment‐resistant depression. PB Fitzgerald et al, Depression & Anxiety, 2009.
This important study demonstrated that a slower form of stimulation delivered to the right frontal lobe–which can be safer and more comfortable for certain patients–can work as well as the standard left-sided treatment. |
|
Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. DM Blumberger et al, The Lancet, 2018.
This important study demonstrated that a shorter and faster type of treatment, called theta burst stimulation, works as well as the standard treatment, which takes 37.5 minutes, and in part led to the FDA approval of theta burst stimulation in 2018. |
|
Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite, Naturalistic, Observational Study of Acute Treatment Outcomes in Clinical Practice. L.L. Carpenter et al, Depression and Anxiety, 2012.
This important study demonstrates that in a real-world setting (as opposed to a tightly controlled research study) 55-60% of patients respond to TMS treatment for depression. |
